Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Mydriatics and Cycloplegics
Ophthalmic cycloplegic and mydriatic agentUsed for cycloplegic refraction and for dilating the pupil for diagnostic purposesContraindicated for use in glaucoma
Mydral, Mydriacyl, Ocu-Tropic, Ophthalmicmyd, Tropicacyl
Mydral/Mydriacyl/Ocu-Tropic/Ophthalmicmyd/Tropicacyl/Tropicamide Ophthalmic Sol: 0.5%, 1%
Instill 1 or 2 drops of a 1% solution into the eye(s), then repeat in 5 minutes. If the patient has not been seen within 20 to 30 minutes, an additional drop to prolong mydriasis may be used.
Instill 1 or 2 drops of a 0.5% solution 15 to 20 minutes before examination.
1% solution: 5 drops/day/eye.0.5% solution: 2 drops/day/eye
Safety and efficacy have not been established.
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
Mydral:- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees FMydriacyl:- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees FOcu-Tropic:- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees FOphthalmicmyd:- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees FTropicacyl :- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Tropicamide is contraindicated in patients with a hypersensitivity to any component of the formulation. Hypersensitivity to anticholinergics may result in behavioral disturbances and psychotic reactions. Tropicamide ophthalmic solution is for topical use only and should never be injected.
Tropicamide is contraindicated in patients with primary glaucoma or a tendency toward narrow angle glaucoma (closed-angle glaucoma). An estimation of the depth of the angle of the anterior chamber should be made prior to the administration of tropicamide to avoid inducing closed-angle glaucoma.
Tropicamide contains benzalkonium chloride, which may be absorbed by contact lenses. Users of soft contact lenses should not administer tropicamide while wearing these lenses.
No differences in safety or efficacy have been identified between geriatric and younger patients. However, increased intraocular pressure may be present in the elderly.
Use tropicamide cautiously in children. The risk of precipitating CNS disturbances in children is possible with the use of tropicamide. Psychotic reactions, behavioral disturbances, and cardiorespiratory collapse have been reported in children being treated with anticholinergics. The safety and efficacy of tropicamide have not been established in infants and neonates.
It is unknown if tropicamide can cause fetal harm when administered during pregnancy or if it can affect reproductive capacity. Therefore, administer tropicamide to a pregnant woman only if clearly needed.
It is not known whether tropicamide is excreted in human milk. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
keratitis / Delayed / Incidence not known
photophobia / Early / Incidence not knownblurred vision / Early / Incidence not knownsinus tachycardia / Rapid / Incidence not known
headache / Early / Incidence not knownxerostomia / Early / Incidence not knownpallor / Early / Incidence not knownvomiting / Early / Incidence not knownnausea / Early / Incidence not known
There are no drug interactions associated with Tropicamide products.
Tropicamide has an anticholinergic effect that blocks the responses of the iris sphincter muscle and the ciliary body muscle to cholinergic stimulation, resulting in mydriasis. The 0.5% solution may be useful for producing mydriasis with little cycloplegia. Administration of the 1% solution also paralyzes accommodation.
Tropicamide is administered ophthalmically.
Ophthalmic route The 1% tropicamide solution has a rapid onset of action producing the maximum mydriatic and cycloplegic effects within 15-60 minutes following topical application to the eye. The duration of both effects is normally 3-8 hours. However, mydriasis may persist for 24 hours in selected patients.